Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor γ cofactor

Molecular and Cellular Proteomics

Volumn 8, Issue 10, 2009, Pages 2212-2226

  Koppen, Arjen ^a,c   Houtman, Rene ^b   Pijnenburg, Dirk ^b   Jeninga, Ellen H ^a,c   Ruijtenbeek, Rob ^b   Kalkhoven, Eric ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PamGene International BV   (Netherlands)

^c NETHERLANDS METABOLOMICS CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CELL NUCLEUS RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; ROSIGLITAZONE; STEROID RECEPTOR COACTIVATOR 1; TELMISARTAN; THYROID HORMONE RECEPTOR INTERACTING PROTEIN 3; UNCLASSIFIED DRUG;

ADIPOCYTE; ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; CELL DIFFERENTIATION; CONFORMATIONAL TRANSITION; HUMAN; HUMAN CELL; LIGAND BINDING; MICROARRAY ANALYSIS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 71049127324     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M900209-MCP200     Document Type: Article

References (72)

1. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (Pubitemid 126663112)
2. Wurtz, J. M., Bourguet, W., Renaud, J. P., Vivat, V., Chambon, P., Moras, D., and Gronemeyer, H. (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3, 87-94
3. Gronemeyer, H., Gustafsson, J. A., and Laudet, V. (2004) Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964
4. Lonard, D. M., and O'malley, B. W. (2007) Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 27, 691-700
5. Rosenfeld, M. G., and Glass, C. K. (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276, 36865-36868
6. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (Pubitemid 27270617)
7. Hu, X., and Lazar, M. A. (1999) The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402, 93-96 (Pubitemid 29533522)
8. Plevin, M. J., Mills, M. M., and Ikura, M. (2005) The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem. Sci. 30, 66-69
9. Barish, G. D., Narkar, V. A., and Evans, R. M. (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Investig. 116, 590-597
10. Lefebvre, P., Chinetti, G., Fruchart, J. C., and Staels, B. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Investig. 116, 571-580
11. Savage, D. B., Tan, G. D., Acerini, C. L. Jebb, S. A., Agostini, M., Gurnell, M., Williams, R. L., Umpleby, A. M., Thomas, E. L., Bell, J. D., Dixon, A. K., Dunne, F., Boiani, R., Cinti, S., Vidal-Puig, A., Karpe, F., Chatterjee, V. K., and O'Rahilly, S. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52, 910-917 (Pubitemid 36384259)
12. Lehrke, M., and Lazar, M. A. (2005) The many faces of PPARgamma. Cell 123, 993-999
13. Tontonoz, P., and Spiegelman, B. M. (2008) Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289-312
14. Lago, R. M., Singh, P. P., and Nesto, R. W. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370, 1129-1136
15. Nissen, S. E., and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
16. Knouff, C., and Auwerx, J. (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25, 899-918
17. Zhang, F., Lavan, B. E., and Gregoire, F. M. (2007) Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007, 32696
18. Sonoda, J., Pei, L., and Evans, R. M. (2008) Nuclear receptors: decoding metabolic disease. FEBS Lett. 582, 2-9 (Pubitemid 350297241)
19. Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., and Gronemeyer, H. (2007) RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6, 793-810
20. Jordan, V. C., and Brodie, A. M. (2007) Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72, 7-25
21. Henderson, G., and Bradley, M. (2007) Functional peptide arrays for high-throughput chemical biology based applications. Curr. Opin. Biotechnol. 18, 326-330
22. Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W., Lazar, M. A., and Chatterjee, V. K. (2000) A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275, 5754-5759
23. Jeninga, E. H., van Beekum, O., van Dijk, A. D., Hamers, N., Hendriks-Stegeman, B. I., Bonvin, A. M., Berger, R., and Kalkhoven, E. (2007) Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. Mol. Endocrinol. 21, 1049-1065
24. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812 (Pubitemid 3006324)
25. Kalkhoven, E., Valentine, J. E., Heery, D. M., and Parker, M. G. (1998) Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17, 232-243 (Pubitemid 28041064)
26. Vega, R. B., Huss, J. M., and Kelly, D. P. (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20, 1868-1876
27. van Beekum, O., Brenkman, A. B., Grøntved, L., Hamers, N., van den Broek, N. J., Berger, R., Mandrup, S., and Kalkhoven, E. (2008) The adipogenic acetyltransferase Tip60 targets activation function 1 of PPARgamma. Endocrinology 149, 1840-1849
28. Lemeer, S., Jopling, C., Naji, F., Ruijtenbeek, R., Slijper, M., Heck, A. J., and den Hertog, J. (2007) Protein-tyrosine kinase activity profiling in knock down zebrafish embryos. PLoS ONE 2, e581 (Pubitemid 351260405)
29. Lemeer, S., Ruijtenbeek, R., Pinkse, M. W., Jopling, C., Heck, A. J., den Hertog, J., and Slijper, M. (2007) Endogenous phosphotyrosine signaling in zebrafish embryos. Mol. Cell. Proteomics 6, 2088-2099
30. Hilhorst, R., Houkes, L., van den Berg, A., and Ruijtenbeek, R. (2009) Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterisation and inhibition studies on protein kinase A. Anal. Biochem. 387, 150-161
31. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956
32. Willson, T. M., Brown, P. J., Sternbach, D. D., and Henke, B. R. (2000) The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550
33. Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuyer, N., Ruiz, P., Unger, T., Staels, B., and Kintscher, U. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54, 3442-3452 (Pubitemid 43334334)
34. Agarwal, A. K., and Garg, A. (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87, 408-411
35. Hummasti, S., and Tontonoz, P. (2006) The peroxisome proliferator- activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. Mol. Endocrinol. 20, 1261-1275
36. Nielsen, R., Grøntved, L., Stunnenberg, H. G., and Mandrup, S. (2006) Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol. Cell. Biol. 26, 5698-5714
37. Wang, Y. X., Lee, C. H., Tiep, S., Yu, R. T., Ham, J., Kang, H., and Evans, R. M. (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113, 159-170 (Pubitemid 36514968)
38. Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., and Spiegelman, B. M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829-839 (Pubitemid 28155321)
39. Lee, J. W., Choi, H. S., Gyuris, J., Brent, R., and Moore, D. D. (1995) Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol. Endocrinol. 9, 243-254
40. Iwahashi, H., Yamagata, K., Yoshiuchi, I., Terasaki, J., Yang, Q., Fukui, K., Ihara, A., Zhu, Q., Asakura, T., Cao, Y., Imagawa, A., Namba, M., Hanafusa, T., Miyagawa, J., and Matsuzawa, Y. (2002) Thyroid hormone receptor interacting protein 3 (trip3) is a novel coactivator of hepatocyte nuclear factor-4alpha. Diabetes 51, 910-914
41. Stafslien, D. K., Vedvik, K. L., De Rosier, T., and Ozers, M. S. (2007) Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Mol. Cell. Endocrinol. 264, 82-89
42. Gowda, K., Marks, B. D., Zielinski, T. K., and Ozers, M. S. (2006) Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-gamma using time-resolved fluorescence resonance energy transfer. Anal. Biochem. 357, 105-115
43. Folkertsma, S., van Noort, P. I., de Heer, A., Carati, P., Brandt, R., Visser, A., Vriend, G., and de Vlieg, J. (2007) The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor alpha ligand-binding domain. Mol. Endocrinol. 21, 30-48
44. Zhou, G., Cummings, R., Hermes, J., and Moller, D. E. (2001) Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation. Methods 25, 54-61 (Pubitemid 32905288)
45. Iannone, M. A., Consler, T. G., Pearce, K. H., Stimmel, J. B., Parks, D. J., and Gray, J. G. (2001) Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 44, 326-337
46. Iannone, M. A., Simmons, C. A., Kadwell, S. H., Svoboda, D. L., Vanderwall, D. E., Deng, S. J., Consler, T. G., Shearin, J., Gray, J. G., and Pearce, K. H. (2004) Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 18, 1064-1081
47. Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C. Y., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., and McDonnell, D. P. (1999) Peptide antagonists of the human estrogen receptor. Science 285, 744-746 (Pubitemid 129505079)
48. Northrop, J. P., Nguyen, D., Piplani, S., Olivan, S. E., Kwan, S. T., Go, N. F., Hart, C. P., and Schatz, P. J. (2000) Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol. Endocrinol. 14, 605-622
49. Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C. Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., and Fowlkes, D. M. (1999) Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U.S.A. 96, 3999-4004
50. Mettu, N. B., Stanley, T. B., Dwyer, M. A., Jansen, M. S., Allen, J. E., Hall, J. M., and McDonnell, D. P. (2007) The nuclear receptor-coactivator interaction surface as a target for Peptide antagonists of the peroxisome proliferator-activated receptors. Mol. Endocrinol. 21, 2361-2377
51. Goodson, M. L., Farboud, B., and Privalsky, M. L. (2007) An improved high throughput protein-protein interaction assay for nuclear hormone receptors. Nucl. Recept. Signal. 5, e002
52. Albers, M:, Kranz, H., Kober, I., Kaiser, C., Klink, M., Suckow, J., Kern, R., and Koegl, M. (2005) Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol. Cell. Proteomics 4, 205-213
53. Kim, S. H., Tamrazi, A., Carlson, K. E., and Katzenellenbogen, J. A. (2005) A proteomic microarray approach for exploring ligand-initiated nuclear hormone receptor pharmacology, receptor selectivity, and heterodimer functionality. Mol. Cell. Proteomics 4, 267-277
54. Jordan, V. C. (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat. Rev. Cancer 7, 46-53
55. Swaby, R. F., Sharma, C. G., and Jordan, V. C. (2007) SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord. 8, 229-239
56. Smith, C. L., and O'Malley, B. W. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71
57. Achermann, J. C., and Jameson, J. (2003) Human disorders caused by nuclear receptor gene mutations. Pure Appl. Chem. 75, 1785-1796
58. Huhtaniemi, I. (2000) Activating and inactivating hormone receptor mutations. Horm. Res. 53, Suppl. 3, 9-16
59. Agostini, M., Gurnell, M., Savage, D. B., Wood, E. M., Smith, A. G., Rajanayagam, O., Games, K. T., Levinson, S. H., Xu, H. E., Schwabe, J. W., Willson, T. M., O'Rahilly, S., and Chatterjee, V. K. (2004) Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 145, 1527-1538
60. Kawakami, K., Shafer, B. K., Garfinkel, D. J., Strathern, J. N., and Nakamura, Y. (1992) Ty element-induced temperature-sensitive mutations of Saccharomyces cerevisiae. Genetics 131, 821-832
61. He, F., Umehara, T., Tsuda, K., Inoue, M., Kigawa, T., Matsuda, T., Yabuki, T., Aoki, M., Seki, E., Terada, T., Shirouzu, M., Tanaka, A., Sugano, S., Muto, Y., and Yokoyama, S. (2007) Solution structure of the zinc finger HIT domain in protein FON. Protein Sci. 16, 1577-1587 (Pubitemid 47195685)
62. Reményi, A., Good, M. C., and Lim, W. A. (2006) Docking interactions in protein kinase and phosphatase networks. Curr. Opin. Struct. Biol. 16, 676-685
63. Ruthenburg, A. J., Li, H., Patel, D. J., and Allis, C. D. (2007) Multivalent engagement of chromatin modifications by linked binding modules. Nat. Rev. Mol. Cell Biol. 8, 983-994
64. Gelman, L., Zhou, G., Fajas, L., Raspé, E., Fruchart, J. C., and Auwerx, J. (1999) p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 274, 7681-7688
65. Zhu, Y., Qi, C., Calandra, C., Rao, M. S., and Reddy, J. K. (1996) Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr. 6, 185-195 (Pubitemid 126682834)
66. Kodera, Y., Takeyama, K., Murayama, A., Suzawa, M., Masuhiro, Y., and Kato, S. (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 275, 33201-33204
67. Zhu, Y., Kan, L., Qi, C., Kanwar, Y. S., Yeldandi, A. V., Rao, M. S., and Reddy, J. K. (2000) Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275, 13510-13516
68. Zamir, I., Zhang, J., and Lazar, M. A. (1997) Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11, 835-846 (Pubitemid 27175291)
69. Kim, G. S., Lee, G. Y., Nedumaran, B., Park, Y. Y., Kim, K. T., Park, S. C., Lee, Y. C., Kim, J. B., and Choi, H. S. (2008) The orphan nuclear receptor DAX-1 acts as a novel transcriptional corepressor of PPARgamma. Biochem. Biophys. Res. Commun. 370, 264-268
70. Nishizawa, H., Yamagata, K., Shimomura, I., Takahashi, M., Kuriyama, H., Kishida, K., Hotta, K., Nagaretani, H., Maeda, N., Matsuda, M., Kihara, S., Nakamura, T., Nishigori, H., Tomura, H., Moore, D. D., Takeda, J., Funahashi, T., and Matsuzawa, Y. (2002) Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation. J. Biol. Chem. 277, 1586-1592
71. Treuter, E., Albrektsen, T., Johansson, L., Leers, J., and Gustafsson, J. A. (1998) A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 12, 864-881
72. Zhu, Y., Qi, C., Jain, S., Rao, M. S., and Reddy, J. K. (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem. 272, 25500-25506